ISSN:0004-8291    

DOI:10.1111/j.1445-5994.1978.tb04770.x

出版商:Blackwell Publishing Ltd    

年代:1978

数据来源: WILEY

ISSN:0004-8291    

DOI:10.1111/j.1445-5994.1978.tb04771.x

出版商:Blackwell Publishing Ltd    

年代:1978

数据来源: WILEY

ISSN:0004-8291    

DOI:10.1111/j.1445-5994.1978.tb04772.x

出版商:Blackwell Publishing Ltd    

年代:1978

数据来源: WILEY

ISSN:0004-8291    

DOI:10.1111/j.1445-5994.1978.tb04773.x

出版商:Blackwell Publishing Ltd    

年代:1978

数据来源: WILEY

ISSN:0004-8291    

DOI:10.1111/j.1445-5994.1978.tb04774.x

出版商:Blackwell Publishing Ltd    

年代:1978

数据来源: WILEY

摘要:

SummaryJaundice complicated the course of disease in 11 (41%) of 27 consecutive patients with multiple myeloma. In only one patient was myeloma cell infiltration of the liver the sole cause of jaundice. One patient was found to have carcinoma of the pancreas. In nine jaundice developed during therapy with the bone marrow stimulant oxymetholone. Liver histology in six of the nine showed cholestatic hepatitis or a predominantly cholestatic reaction; clinical events were consistent with oxymetholone‐induced cholestasis in the remaining three. In addition to oxymetholone all patients were receiving intermittent therapy with melphalan, prednisolone and procarbazine, but such therapy was not temporally related to the onset of jaundice. All jaundiced patients were HBsAg negative. Of the 19 patients treated with oxymetholone for refractory anaemia, nine (47%) developed jaundice. The reason for such a high complication rate is obscure. Three of these patients, who showed a severe cholestatic hepatitis, died in acute liver failure. These results indicate that high doses of oxymetholone should be used with great care in the therapy of refractory anaemia in multiple myelom

ISSN:0004-8291    

DOI:10.1111/j.1445-5994.1978.tb02397.x

出版商:Blackwell Publishing Ltd    

年代:1978

数据来源: WILEY

ISSN:0004-8291    

DOI:10.1111/j.1445-5994.1978.tb04775.x

出版商:Blackwell Publishing Ltd    

年代:1978

数据来源: WILEY

ISSN:0004-8291    

DOI:10.1111/j.1445-5994.1978.tb04776.x

出版商:Blackwell Publishing Ltd    

年代:1978

数据来源: WILEY

ISSN:0004-8291    

DOI:10.1111/j.1445-5994.1978.tb04777.x

出版商:Blackwell Publishing Ltd    

年代:1978

数据来源: WILEY

摘要:

SummaryClinical pharmacology and efficacy of benorylate in patients with rheumatoid arthritis. G. D. Champion, R. 0. Day, P. D. Paull, G. G. Graham, M. S. Owen, A. L Haski and L. Hills,Aust. N.Z. J. Med.,1978, 8, pp. 22–28.Benorylate, an ester of aspirin and paracetamol, was evaluated in 24 adult patients with rheumatoid arthritis. Benorylate dosage was individualized over a three week period, and subsequently, the patients were randomly allocated to continue dosage with benorylate or to change to placebo for one week. All measures of inflammation and pain worsened on the change to placebo. At the end of the double‐blind phase, significant differences were noted between the group who stayed on benorylate and the placebo group in the following parameters: pain index, articular index, functional index, the number of analgesic tablets taken, the duration of daytime rest and patients' and investigators' global assessments. There was no significant differences in the time to walk 50 feet while the differences in the duration of morning stiffness and grip strength were of marginal significance. The degree of relapse in the placebo group was most marked in patients who had attained plasma concentrations of salicylate above 130 μglml prior to the change to placebo. The mean adjusted daily dose of benorylate (±SD) was 11‐3 (±0–7) g and the mean plasma concentration of salicylate was 175 (

ISSN:0004-8291    

DOI:10.1111/j.1445-5994.1978.tb02398.x

出版商:Blackwell Publishing Ltd    

年代:1978

数据来源: WILEY